Comparative Pharmacology
Head-to-head clinical analysis: ETHINYL ESTRADIOL AND NORELGESTROMIN versus PREMPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHINYL ESTRADIOL AND NORELGESTROMIN versus PREMPRO.
ETHINYL ESTRADIOL AND NORELGESTROMIN vs PREMPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin release via negative feedback on pituitary; progestin (norelgestromin) thickens cervical mucus and inhibits ovulation.
PREMPRO is a combination of conjugated estrogens and medroxyprogesterone acetate. Estrogens bind to estrogen receptors, activating gene transcription and exerting effects on various tissues. Medroxyprogesterone acetate is a progestin that suppresses endometrial proliferation, reducing the risk of endometrial hyperplasia associated with unopposed estrogen therapy.
One transdermal patch (releasing 0.035 mg ethinyl estradiol and 0.150 mg norelgestromin per 24 hours) applied once weekly for 3 weeks, followed by 1 week patch-free.
One tablet orally once daily; each tablet contains conjugated estrogens 0.625 mg and medroxyprogesterone acetate 2.5 mg or 5 mg.
None Documented
None Documented
Ethinyl estradiol has a terminal elimination half-life of approximately 13-27 hours (mean ~17 hours). Norelgestromin has a terminal half-life of about 28 hours. These half-lives support once-weekly dosing of the transdermal system, achieving steady-state by the second application.
The terminal elimination half-life of conjugated estrogens (primarily estrone and equilin) ranges from 10-24 hours (mean ~15 hours) after oral administration. This supports once-daily dosing with steady-state achieved within 5-7 days.
Ethinyl estradiol and norelgestromin are excreted primarily via urine and feces. Ethinyl estradiol undergoes extensive metabolism; about 40% is excreted in urine and 60% in feces as glucuronide and sulfate conjugates. Norelgestromin is metabolized to norgestrel and other metabolites; approximately 45% is excreted in urine and 35% in feces.
Conjugated estrogens are primarily excreted in urine (renal elimination accounts for ~50-80% of total clearance) as glucuronide and sulfate conjugates. A smaller fraction undergoes biliary excretion (~10-20%) and is eliminated in feces via enterohepatic circulation.
Category D/X
Category C
Estrogen
Estrogen/Progestin Combination